Cover Image

Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy

Current guidelines favor the use of chelating agents (d-penicillamine, trientine) in first line therapy of symptomatic Wilson disease patients. Development of chelator induced immunological adverse events are a concern especially under d-penicillamine therapy. This study assessed the prevalence of c...

Full description

Saved in:
Bibliographic Details
Main Authors: Seeßle, Jessica (Author) , Gotthardt, Daniel (Author) , Schäfer, Mark (Author) , Gohdes, Annina (Author) , Pfeiffenberger, Jan (Author) , Ferenci, Peter (Author) , Stremmel, Wolfgang (Author) , Weiss, Karl Heinz (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Journal of inherited metabolic disease
Year: 2015, Volume: 39, Issue: 1, Pages: 125-130
ISSN:1573-2665
DOI:10.1007/s10545-015-9866-0
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10545-015-9866-0
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1007/s10545-015-9866-0
Get full text
Author Notes:Jessica Seessle, Daniel Nils Gotthardt, Mark Schäfer, Annina Gohdes, Jan Pfeiffenberger, Peter Ferenci, Wolfgang Stremmel, Karl Heinz Weiss
Description
Summary:Current guidelines favor the use of chelating agents (d-penicillamine, trientine) in first line therapy of symptomatic Wilson disease patients. Development of chelator induced immunological adverse events are a concern especially under d-penicillamine therapy. This study assessed the prevalence of co-existing or therapy-related immune-mediated diseases in Wilson disease patients, and evaluated the role of antinuclear antibodies in therapy monitoring.
Item Description:Published online: 12 June 2015
Gesehen am 27.05.2020
Physical Description:Online Resource
ISSN:1573-2665
DOI:10.1007/s10545-015-9866-0

Similar Items